Sun, Nov 05, 2017 - Page 15 News List

Diabetes devices move from crude pins to slick tech

By Natasha Rausch  /  Bloomberg

Diabetes devices might be having their iPhone moment.

For decades, the daily routine of diabetics involved painful needles, finger-pricking lancets and imprecise glucose meters. Now, manufacturers have begun incorporating the slick and user-friendly designs of Silicon Valley, linking to smartphones and other tech devices.

“This is a crossroads for diabetes technology,” said Raj Denhoy, an analyst at Jefferies LLC in New York.

September marked a breakthrough in the US, as regulators approved the first monitoring system that does not need a blood sample, Abbott Laboratories’ FreeStyle Libre.

The new devices do away with fingerpricks, changing an unpleasant, several-times-a-day routine into quiet monitoring in the background through a sensor worn on the back of the upper arm.

Other companies have been left behind. Johnson & Johnson is closing its insulin-pump unit after failing to keep up with Medtronic PLC. DexCom Inc, the leader in glucose-monitoring systems, lost one-thirds of its market value on Sept. 28 after Abbott’s Libre got approval.

During DexCom’s earnings conference call on Wednesday, executives, peppered with questions about the Libre, said the company hopes to introduce its own fingerprick-free device before the end of next year.

The comments about next-generation monitors helped assuage investors’ concerns about DexCom’s prospects, sending the stock up 9.5 percent in the two trading days following the results.

“Companies who succeed will be those who can figure out this convergence of healthcare and technology,” said Arda Ural, a partner at Ernst & Young LLP in New York. “And they’re very different animals to bring together.”

For the winners, the potential market is huge. Diabetes device sales totaled US$14 billion in the US last year, according to Ernst & Young.

For now, the bulk of the sales are to the 1.25 million US diabetes patients with the most severe form of the disease, type 1. Because their pancreas cannot produce insulin, those patients have to constantly monitor their blood sugar and frequently inject themselves with insulin when it spikes.

There is a larger, mostly untapped market: The about 20 million Americans with type 2 diabetes whose body’s ability to use insulin fades slowly over time and who do not regularly use tools to manage their disease.

Yet, some patients have been waiting for decades for better devices to control a condition that, unchecked, can lead to complications including kidney damage and heart disease.

Aaron Kowalski, chief mission officer of diabetes research foundation JDRF, was diagnosed as a 13-year-old in the 1980s. At the time, people measured their glucose by urinating on a stick or placing a drop of blood on a color strip that gave a rough number.

“It was barbaric,” he said.

Abbott’s Libre is to arrive in the US soon. It has already been sold to 400,000 people internationally.

Dexcom, despite the recent blow, has been making strides as well. Its G4 and G5 sensors stick on the body and are only calibrated twice a day with a finger prick.

In September, the San Diego company teamed with Fitbit Inc to link its devices with the latest Fitbit Ionic smartwatch. The companies hope to get the product out next year.

Unlike many consumer products, diabetes devices face two major hurdles — the US Food and Drug Administration (FDA) and health insurers.

This story has been viewed 1617 times.

Comments will be moderated. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned.

TOP top